On August 26, Biohaven announced a global licensing agreement with SK Biopharmaceuticals covering opakalim, the company’s primary epilepsy candidate. The transaction included up to $795 million in upfront and milestone payments along with tiered royalties, with Biohaven receiving $350 million at closing and an additional $50 million scheduled for 2027, plus potential milestone and royalty payments reaching $150 million or more.
The timing of the agreement aligned with Biohaven’s August 10, 2026 earnings report, which disclosed quarterly net losses exceeding $100 million. Under the arrangement, SK Biopharmaceuticals obtained exclusive worldwide rights to Biohaven’s Kv7 ion channel platform while assuming development costs and certain obligations to Knopp Biosciences. Biohaven’s CEO characterized the structure as validation of the company’s ability to monetize its pipeline through partnerships rather than relying solely on capital markets.
Opakalim’s commercial potential rested on clinical trial results demonstrating efficacy in seizure reduction. In an idiopathic generalized epilepsy study, median time to a second seizure reached 141 days on opakalim compared to 47 days on placebo, with one-third of patients remaining seizure-free through the 24-week period. Focal epilepsy data showed 54% of patients in an open-label extension study achieving at least 50% seizure frequency reduction over any six-month interval. The compound’s once-daily dosing without titration represented a potential advantage over existing antiseizure medications.
The deal structure required Biohaven to relinquish full ownership of an asset it viewed as potentially blockbuster, retaining only royalties in the mid-teens to low twenties percentage range. Biohaven remained a cash-burning clinical-stage company, having reported $137.3 million in net losses for the second quarter against $270.5 million in total liquid assets as of June 30. Pivotal RISE3 trial results in focal epilepsy, underlying the licensing arrangement, were not expected until the second half of 2026. Hedge fund ownership held steady at 47 funds while short interest represented 15.09% of float, indicating market uncertainty regarding the deal’s impact on the company’s trajectory.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI